1Q24 Reported With Preparations Continuing For Tecarfarin Phase 3

Tecarfarin Receives Orphan Drug Designation For Second Indication

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial

Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin

Robert LeBoyer

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community. Your name, email, zip, and investor type is all it takes to open the door to research reports, favorites tracking, and virtual and in-person roadshows / conferences. Even exclusive investment opps.

Take it to the next level. It doesn’t cost a penny.

<p>Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.</p>


Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

Healthcare

Biotechnology

Cadrenal Therapeutics Inc.

Footer menu

Main menu

Show form on click button

<h3 style="text-align: center;"><span style="color: #333399;">Enjoying Channelchek?</span></h3>
<p style="text-align: center;">There&#8217;s more to explore!</p>
<p style="text-align: center;"><a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research,<br />
Exclusive Videos, Live Event Updates, and more!</p>
<p style="text-align: center;">It&#8217;s absolutely free to join.</p>
<p><a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" srcset="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg 300w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1024x876.jpg 1024w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-768x657.jpg 768w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1536x1314.jpg 1536w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-2048x1752.jpg 2048w" sizes="(max-width: 351px) 100vw, 351px" /></a></p>
<p><script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script></p>


Cadrenal Therapeutics Inc. (CVKD)

Addressing Unmet Anticoagulation Needs In Orphan Populations

Fundamental Analysis:

Rating: Log in to view

1Q24 Reported With Preparations Continuing For Tecarfarin Phase 3 (CVKD)

Tecarfarin Receives Orphan Drug Designation For Second Indication (CVKD)

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial (CVKD)

Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin (CVKD)

Inbox Intel from Channelchek.